Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393311 | 0.99 | TSHR (0.47) | TSHRLPAR1TDP1CCR6PAX8 | |
| SCHEMBL392054 | 0.97 | TSHR (0.49) | TSHRLPAR1TDP1CCR6PAX8 | |
| SCHEMBL391872 | 0.91 | TSHR (0.50) | TSHRLPAR1TDP1CCR6PAX8 | |
| SCHEMBL16295819 | 0.87 | TSHR (0.51) | TSHRLPAR1TDP1CCR6PAX8 | |
| SCHEMBL16306415 | 0.85 | TSHR (0.49) | TSHRLPAR1TDP1CCR6PAX8 | |
| SCHEMBL8030776 | 0.85 | CCR6 (0.54) | TSHRLPAR1TDP1CCR6PAX8 | |
| SCHEMBL3075203 | 0.84 | ACHE (0.52) | TSHRLPAR1TDP1ALOX5LPAR5 | |
| SCHEMBL4668991 | 0.83 | TSHR (0.54) | TSHRLPAR1TDP1ALOX5LPAR5 | |
| SCHEMBL393867 | 0.83 | TSHR (0.47) | TSHRLPAR1TDP1ALOX5LPAR5 | |
| SCHEMBL3814940 | 0.83 | ACHE (0.54) | TSHRLPAR1TDP1ALOX5LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362015-B2 | Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| US-8362015-B2 | Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| US-8334284-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334284-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334284-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| EP-2084154-B1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER IP GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| EP-2084154-B1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER IP GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2209776-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDER | Bayer Schering Pharma AG (DE) | 2010-07-28 | — | — | EP | disclosed |
| EP-2084154-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009007026-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007026-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007027-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008022786-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008022786-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007093328-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | PLG, AADAC, DNPEP | TSHR 3674/4885LPAR1 3439/4885TDP1 619/4885 |
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | TSHR 2106/4885LPAR1 3822/4885TDP1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.